Zheng Quan Zhi Xing·2025-08-01 00:11Group 1: New Coordinates (603040) - The company expects overseas revenue to account for 43.17% of total revenue in 2024, with growth driven by the expansion of domestic self-owned brand customers [1] - Over 90% of the company's clients are automotive manufacturers, covering both domestic and international passenger and commercial vehicle markets [1] - The company is a high-tech enterprise with full industry chain R&D capabilities, focusing on high precision and material utilization in cold forming technology [1] - The company is actively expanding its customer base and market share while enhancing communication with overseas clients [1] - The company is addressing annual decline issues through improved internal control and on-site management [1] - Collaboration with Zhejiang Tuoman Intelligent Technology Co., Ltd. and Mr. Sun Lishong is ongoing, with related products currently in the R&D stage [1] Group 2: Weili Medical (603309) - The company reported that production costs at overseas factories are slightly higher than those in China, but savings in customer shipping and storage costs are expected to keep gross margins stable [2] - The gross margin for urology products exceeds 70%, driven by domestic brand effects and revenue growth from import substitution and overseas market expansion [2] - Since 2023, the company has intensified its efforts to export urology products, achieving significant results with sustained high growth in external sales over the past two years [2] - The company's production capacity is concentrated in five cities, with plans to establish factories in Indonesia and Mexico to mitigate geopolitical risks and enhance automation levels [2]